Advanced Prostate Cancer Consensus Conference (APCCC)
In advanced prostate cancer, rapid and successful drug development has resulted in multiple treatment options that require careful decision-making for individual patients. Clinicians face the increasingly difficult task of choosing from multiple potentially effective treatments that also are costly and potentially toxic. Further developments in novel next-generation imaging methods, biomarkers, ...
read more ↘
read more ↘
PARP Inhibition (Dissected): Determining Who Benefits in mCRPC
Comments 0
Login to view comments.
Click here to Login